ArticleFrontiers in medicine2026
Case Report: Hepatitis B virus reactivation following rituximab therapy in a patient receiving maintenance hemodialysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate a case of hepatitis B virus reactivation (HBV-R) in a post-lymphoma patient with renal transplantation and long-term maintenance hemodialysis (MHD), and to explore prevention strategies for high-risk populations. Methods: Patient records were reviewed for dialysis history, HBV markers, and liver function. Environmental sampling was conducted, and a multidisciplinary team established individualized management as well as optimized screening and vaccination strategies. Results: The patient had undergone maintenance hemodialysis since February 2023 with stable hepatitis B virus (HBV) serology. In March 2024, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA tested positive. The patient had received intermittent chemotherapy and rituximab at another hospital during dialysis. Following reactivation, the patient was transferred to dedicated dialysis equipment with isolation nursing care, strict infection control measures, and environmental monitoring. A multidisciplinary team refined high-risk patient screening and reinforced vaccination programs. Conclusion: Hemodialysis patients under prolonged immunosuppression face elevated HBV reactivation risk. Early identification and risk-based management are essential to reduce adverse impacts on patient safety and healthcare quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.